14 - 15 May, 2019 | Hotel Novotel Amsterdam Schiphol Airport, Amsterdam, Netherlands
Conference Day Two
9:10 am - 9:45 am Broadening Patient Reach in Emerging Markets
- Understand the opportunity for growth in emerging markets
- Explore the challenges and opportunities of utilizing both government and out-of-pocket strategies to maximize patient access and commercialization in emerging markets
- Explore models with peer-proven success to expand patient reach, with case studies
9:45 am - 10:20 am Case Study: Manufacturing Biosimilars for Checkpoint Inhibitors
- Ensure biosimilarity and high productivity with upstream process modulation
- Utilise novel SPOT™ and SLIM™ technologies on the CHOBC® platform to reduce COGs
- Combine biosimilar checkpoint inhibitors to reduce healthcare expenditures
10:20 am - 10:50 am Networking Coffee Break
10:50 am - 11:25 am Overcome the Bottleneck Limiting Patient Access in the UK Home Care System
- Ensure your post market success and maximize patient access in the UK by navigating the HomeCare system
- Consider the business implications of the failure to deliver biosimilars to patients in the UK
- Optimise your supply chain by exploring methods to guarantee the delivery of biosimilars to patients in the UK
Kalveer Flora
Specialist Pharmacist Rheumatology and BiosimilarsLondon North West Healthcare NHS Trust
11:25 am - 12:00 pm Exploring Key Strategies to Avoid Completion
- Explore the competitive landscape and learn to differentiate yourself by improving formulation and discuss other defining factors
- Design effective methods for successful market access
- Benchmark your own practice with an SME with a case study for low competition
12:00 pm - 12:40 pm Payer Perspectives on Value Drivers for Biosimilars
- Undertake a Healthcare Fiscal overview, exploring the medicine funding landscape for biosimilars and the New NHS CQUINS on Biosimilars and its implementation
- Hear how payers are aligning biosimilars with innovative parent brands to streamline patient care settings
- Consider what the differential payer value drivers are for switching from parent brand to biosimilar, compared to biosimilar to biosimilar
- Bridge the uncertainty gap between payers &pharma – the shifting paradigm
Omar Ali
Advisor on value Based Pricing, US Embassy, Lecturer Value Based Pricing & Outcomes Based Innovative Contracting, University of Portsmouth & Former Member Adoption & Impact Panel, NICEUniversity of Portsmouth
12:40 pm - 1:40 pm Networking Lunch
1:40 pm - 2:20 pm Value Based Agreements with Biosimilars
- Gain a comprehensive knowledge of what a value based agreement is and its significance to the biosimilars industry
- Learn how to construct your own value based agreement
- Explore both market access and payer perspectives on risk sharing
Omar Ali
Advisor on value Based Pricing, US Embassy, Lecturer Value Based Pricing & Outcomes Based Innovative Contracting, University of Portsmouth & Former Member Adoption & Impact Panel, NICEUniversity of Portsmouth
2:20 pm - 2:55 pm Patients and the Challenge of Switching
- Consider how a patient may feel powerless when being forced/ encouraged to switch to a biosimilar
- Discuss how the science behind a biosimilar, with respect to complexity, may add to patients skepticism and the importance to educate patients about their safety and efficacy to allay their fears
- Explore the commercial significance of switching, with respect to the necessity to switch established patients between brands to allow hospitals to avoid only using biosimilars for new treatment starts
Sue Caleo-Naeyaert
Global Head Government Affairs, Policy and PharmaceconomicsFresenius Kabi SwissBioSim
2:55 pm - 3:25 pm Networking Coffee Break
3:25 pm - 4:10 pm Panel Discussion: The Market Value of Real World Evidence in the Education of Stakeholders
Speakers:
Sue Caleo-Naeyaert Global Head Government Affairs, Policy and Pharmaceconomics Fresenius Kabi SwissBioSim
Kalveer Flora Specialist Pharmacist Rheumatology and Biosimilars London North West Healthcare NHS Trust
Omar Ali Advisor on value Based Pricing, US Embassy, Lecturer Value Based Pricing & Outcomes Based Innovative Contracting, University of Portsmouth & Former Member Adoption & Impact Panel, NICE University of Portsmouth
Sue Caleo-Naeyaert Global Head Government Affairs, Policy and Pharmaceconomics Fresenius Kabi SwissBioSim
Kalveer Flora Specialist Pharmacist Rheumatology and Biosimilars London North West Healthcare NHS Trust
Omar Ali Advisor on value Based Pricing, US Embassy, Lecturer Value Based Pricing & Outcomes Based Innovative Contracting, University of Portsmouth & Former Member Adoption & Impact Panel, NICE University of Portsmouth
- Explore the contentious idea that real world evidence is an unnecessary undertaking in the commercialisation of biosimilars
- Consider the pros and cons of incremental registration for multiple indications
- Hear the views of a sponsoring company, pharmacist, and payer
Sue Caleo-Naeyaert
Global Head Government Affairs, Policy and PharmaceconomicsFresenius Kabi SwissBioSim
Kalveer Flora
Specialist Pharmacist Rheumatology and BiosimilarsLondon North West Healthcare NHS Trust
Omar Ali
Advisor on value Based Pricing, US Embassy, Lecturer Value Based Pricing & Outcomes Based Innovative Contracting, University of Portsmouth & Former Member Adoption & Impact Panel, NICEUniversity of Portsmouth
4:10 pm - 4:55 pm Fire-Side Chat: Objection Handling Q&A
- Confront trials by engaging with a physician to explore how manufacturers and regulators hope to maintain the trust of the public in a relatively novel class of medicines, faced with such potential for future variability, mistrust and misinformation
- Explore how the risks of extrapolation of indications can be minimised and the significance of this practice for the biosimilar industry
- Bring your own challenges to the forefront of the industry and discuss how to tackle prescriber objections
